Trials / Active Not Recruiting
Active Not RecruitingNCT06220669
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3541860 | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2024-03-19
- Primary completion
- 2025-10-18
- Completion
- 2026-07-01
- First posted
- 2024-01-24
- Last updated
- 2026-04-07
Locations
20 sites across 7 countries: United States, France, Italy, Latvia, Poland, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06220669. Inclusion in this directory is not an endorsement.